Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LpfiledCriticalPurdue Pharma Lp
Priority claimed from PCT/IB2013/000746external-prioritypatent/WO2013156850A1/en
Publication of MA20150351A1publicationCriticalpatent/MA20150351A1/en
Publication of MA37466B2publicationCriticalpatent/MA37466B2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
L'invention concerne, dans certains modes de réalisation, un procédé de traitement ou de prévention d'une réponse pharmacodynamique indésirable induite par un opioïde, comprenant l'administration à un patient qui en a besoin d'une quantité efficace de buprénorphine.Embodiments of the invention provide a method of treating or preventing an undesirable pharmacodynamic response induced by an opioid, comprising administering to a patient in need thereof an effective amount of buprenorphine.
MA37466A2012-04-172013-04-17
Systems and methods for treating an undesirable pharmacodynamic response induced by an opioid
MA37466B2
(en)
pde9 inhibitors with imidazo triazinone main chain, pharmaceutical composition comprising them, use of said inhibitors and process for their preparation
method of preventing, treating, ameliorating or inhibiting an immune system disorder, use of a therapeutically effective amount of at least one desferrioxamine metal complex (metal-dfo complex), composition and pharmaceutical composition.